Trials / Completed
CompletedNCT04469556
Pancreatic Adenocarcinoma Signature Stratification for Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated into this phase II trial are a number of laboratory components including molecular profiling, patient derived organoid establishment, and drug testing sensitivity and other biomarkers.
Detailed description
The two chemotherapy regimens GA and mFFX remain standard treatment options without biomarkers to predict response. PASS-01 will for the first time explore progression free survival differences in the two standard backbone regimens used in the advanced setting. Biomarker driven strategies in pancreatic ductal adenocarcinoma (PDAC) are lacking, perhaps accounting for a large number of failed phase II studies. This study will evaluate two standard of care chemotherapy regimens, but will also explore high content molecular profiling, chemotherapy sensitivity signatures, GATA6 and other putative biomarkers as predictors of response to chemotherapy. In addition, the use of patient derived organoid models for personalized medicine in PDAC will continue to develop within this study. Approximately 150 patients diagnosed with untreated metastatic pancreatic cancer will be randomized to either arm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Folfirinox | Chemotherapy |
| DRUG | Gemcitabine/nab-paclitaxel | Chemotherapy |
Timeline
- Start date
- 2020-10-14
- Primary completion
- 2025-03-05
- Completion
- 2025-03-05
- First posted
- 2020-07-14
- Last updated
- 2026-02-20
Locations
6 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT04469556. Inclusion in this directory is not an endorsement.